PMEDAP
Latest Information Update: 17 Apr 2002
Price :
$50 *
At a glance
- Originator Rega Institute for Medical Research
- Developer Nonindustrial source; Rega Institute for Medical Research
- Class Antivirals; Purines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cytomegalovirus infections; Epstein-Barr virus infections; Hepatitis B; HIV infections
Most Recent Events
- 31 Jul 2000 Profile reviewed but no significant changes made
- 30 Mar 1997 Preclinical development for Cancer in Czech Republic (Unknown route)
- 12 Aug 1996 Preclinical development for Cytomegalovirus infections in Belgium (Unknown route)